24-Hour control with a latanoprost-timolol fixed combination vs timolol alone

Archives of Ophthalmology

Volumn 124, Issue 11, 2006, Pages 1553-1557

  Konstas, Anastasios G P ^a   Lake, Symeon ^a   Economou, Athanasios I ^a   Kaltsos, Kostantinos ^a   Jenkins, Jessica N ^b   Stewart, William C ^b,c  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

^b University of South Carolina   (United States)

^c UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIMATOPROST; BRIMONIDINE; BRINZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; LATANOPROST PLUS TIMOLOL; LATANOPROST PLUS TIMOLOL MALEATE; TIMOLOL MALEATE; TRAVOPROST; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CONTROL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EYE DISCOMFORT; FEMALE; HUMAN; INTRAOCULAR PRESSURE; MALE; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTIHYPERTENSIVE AGENTS; CIRCADIAN RHYTHM; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; PROSTAGLANDINS F, SYNTHETIC; TIMOLOL; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 33750998173     PISSN: 00039950     EISSN: 00039950     Source Type: Journal    
DOI: 10.1001/archopht.124.11.1553     Document Type: Article

References (29)

1. Pfeiffer N; German Latanoprost Fixed Combination Study Group. A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol. 2002;240:893-899.
2. Higginbotham EJ, Feldman R, Stiles M, Dubiner H. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch Ophthalmol. 2002;120:915-922.
3. Alm A, Stjernschantz J; Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning: a comparison with timolol. Ophthalmology. 1995;102:1743-1752.
4. Konstas AG, Nakos E, Tersis I, Lallos NA, Leech LN, Stewart WC. A comparison of once-daily morning vs evening dosing of concomitant latanoprost/timolol. Am J Ophthalmol. 2002;133:753-757.
5. Konstas AGP, Maltezos AC, Gandi S, Hudgins AC, Stewart WC. Comparison of the 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol in patients with open-angle glaucoma. Am J Ophthalmol. 1999;128:15-20.
6. Konstas AG, Boboridis K, Tzetzi D, Kallinderis K, Jenkins JN, Stewart WC. Twenty-four-hour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy. Arch Ophthalmol. 2005;123:898-902.
7. Stewart WC, Holmes KT, Johnson MA. Washout periods for brimonidine 0.2% and latanoprost 0.005%. Am J Ophthalmol. 2001;131:798-799.
8. Book SA. Essentials of Statistics. New York, NY: McGraw-Hill Book Co; 1978:117-122, 205-215.
9. Konstas AGP, Mantziris DA, Cate EA, Stewart WC. Effect of timolol on the diurnal intraocular pressure in exfoliation and primary open-angle glaucoma. Arch Ophthalmol. 1997;115:975-979.
10. Konstas AGP, Mantziris DA, Stewart WC. Diurnal intraocular pressure in untreated exfoliation and primary open-angle glaucoma. Arch Ophthalmol. 1997;115:182-185.
11. Orzalesi N, Rossetti L, Bottoli A, Fumagalli E, Fogagnolo P. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Arch Ophthalmol. 2003;121:453-457.
12. Duff GR. A double-masked crossover study comparing the effects of carteolol 1% and 2% on intra-ocular pressure. Acta Ophthalmol (Copenh). 1987;65:618-621.
13. Konstas AG, Lake S, Maltezos AC, Holmes KT, Stewart WC. Twenty-four hour intraocular pressure reduction with latanoprost compared with pilocarpine as third-line therapy in exfoliation glaucoma. Eye. 2001;15:59-62.
14. Mundorf TK, Cate EA, Sine CS, Otero DW, Stewart JA, Stewart WC. The safety and efficacy of switching timolol maleate 0.5% solution to timolol hemihydrate 0.5% solution given twice daily. J Ocul Pharmacol Ther. 1998;14:129-135.
15. Stewart WC, Day DG, Stewart JA, Schuhr J, Latham KE. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in openangle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;131:631-635.
16. Siegel S. Nonparametric Statistics for the Behavioral Sciences. New York, NY: McGraw-Hill Book Co; 1956:63-67.
17. Stewart WC, Stewart JA, Day D, Sharpe ED. Efficacy and safety of timolol maleate/latanoprost fixed combination versus timolol maleate and brimonidine given twice daily. Acta Ophthalmol Scand. 2003;81:242-246.
18. Stewart WC, Stewart JA, Day DG, Sharpe ED, Jenkins JN. Efficacy and safety of the latanoprost/timolol maleate fixed combination versus concomitant brimonidine and latanoprost therapy. Eye. 2004;18:990-995.
19. Diestelhorst M, Larsson LI; European Latanoprost Fixed Combination Study Group. A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension. Br J Ophthalmol. 2004;88:199-203.
20. Calissendorff B, Sjoquist B, Hogberg G, Grunge-Lowerud A. Bioavailability in the human eye of a fixed combination of latanoprost and timolol compared to monotherapy. J Ocul Pharmacol Ther. 2002;18:127-131.
21. Shin DH, Feldman RM, Sheu W-P. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. Ophthalmology. 2004;111:276-282.
22. Konstas AG, Kozobolis VP, Lallos N, Christodoulakis E, Stewart JA, Stewart WC. Daytime diurnal curve comparison between the fixed combinations of latanoprost 0.005%/timolol maleate 0.5% and dorzolamide 2%/timolol maleate 0.5%. Eye. 2004;18:1264-1269.
23. Camras CB; United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month, masked, multicenter trial in the United States. Ophthalmology. 1996;103:138-147.
24. Watson P, Stjernschantz J; Latanoprost Study Group. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology. 1996;103:126-137.
25. Stewart WC. Influence on the diurnal curve of the intraocular pressure with current ocular hypotensive. Rev Ophthalmol. 2001;8:128-132.
26. Stewart WC. Clinical Practice of Glaucoma. Thorofare, NJ: Slack Inc; 1990:1-40, 149-196.
27. Shields MB. Textbook of Glaucoma. Baltimore, Md: Williams & Wilkins; 1987:45-70.
28. Brubaker RF, Nagataki S, Bourne WM. Effect of chronically administered timolol on aqueous humor flow in patients with glaucoma. Ophthalmology. 1982;89:280-283.
29. Hayreh SS, Podhajsky P, Zimmerman MB. Beta-blocker eyedrops and nocturnal arterial hypotension. Am J Ophthalmol. 1999;128:301-309.